A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Eligible age
4+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.
Sponsor: Rhythm Pharmaceuticals, Inc.
Where it's recruiting
Birmingham
Aurora
Chicago
Boston
Saint Paul
New York
Philadelphia
Seattle
Source: ClinicalTrials.gov · NCT06760546 · last updated 2026-02-12